<DOC>
	<DOCNO>NCT01570205</DOCNO>
	<brief_summary>The objective study investigate safety , tolerability , pharmacokinetics XG-102 follow iv infusion single escalate dose 10 , 40 , 80 µg/kg XG-102 healthy male volunteer</brief_summary>
	<brief_title>Safety , Tolerability PK Single iv Infusion 10 , 40 , 80 µg/kg XG-102 Administered Healthy Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Inflammation</mesh_term>
	<criteria>Healthy male volunteer Age ≥ 18 ≤ 45 year BP : 100 150 mm Hg systolic , 50 95 mm Hg diastolic pulse rate : 50 100 bpm . Body mass index 18.5 30.0 kg/m2 body weight 50 100 kg range . Are able communicate cooperate Investigator his/her staff Healthy basis medical history , physical examination finding , clinical laboratory test result , vital sign measurement , digital 12 lead ECG reading Written inform consent obtain Male subject partner childbearing potential use adequate contraception , least four week administration study medication . Heavy smoker , i.e . 10 cigarette per day Participation clinical trial previous 4 week Loss 500 mL blood 3 month period screen visit study Existence surgical medical condition might relevantly interfere subject safety , distribution , metabolism excretion drug study assessment , i.e . impaired renal hepatic function , diabetes mellitus , thyroid function abnormality include abnormal thyroid hormone value Screening evaluation , cardiovascular abnormality , chronic symptom pronounce constipation diarrhea condition associate total partial obstruction urinary tract . History alcohol drug abuse last 3 year . Positive result drug Screening . Clinically significant abnormal laboratory value Screening baseline evaluation . A history serious adverse reaction hypersensitivity drug medicine Presence history allergy require acute chronic treatment ( seasonal allergic rhinitis require treatment may tolerate ) . Positive result serology examination HBV , HCV , HIV tuberculosis History serious mental disorder . Need prescription medication within 30 day prior administration drug and/or nonprescription medication within 7 day prior administration drug anticipate need concomitant medication study . Volunteers unwilling comply provision protocol Symptoms significant ( upon Investigator 's medical judgment ) somatic mental illness two week period precede drug administration .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>April 2012</verification_date>
</DOC>